John Blenis
Showed early on that rapamycin blocks S6 kinase, then worked out how mTORC1 drives cell growth through its two main translation targets, S6K1 and 4E-BP1. His lab also found, in parallel with the Sabatini lab, that mTORC1 phosphorylates Grb10, a feedback brake on insulin signalling
Weill Cornell Medicine, New York · Harvard Medical School (1989–2014) · PhD, Michigan State (1983)
Blenis Lab, Weill Cornell Medicine (New York, New York, USA) ↗ Lab lineagetrained under Raymond L. Erikson → ORCID0000-0003-3622-2337 ↗
John Blenis trained at UC Berkeley and Michigan State, did postdoctoral work at Harvard, and built his career at Harvard Medical School before moving to Weill Cornell Medicine in New York.
In the early days of the field, Blenis studied the ribosomal S6 kinases and showed, alongside other groups, that activation of p70 S6 kinase (S6K) depends on PI3-kinase and is blocked by rapamycin, making it one of the first known components of what we now call the PI3K–mTORC1 pathway. His lab helped define how this pathway is switched on through AKT, the Rheb GTPase and the TSC2 tumour suppressor (MAN2002, TEE2002), and how mTORC1 and S6K ultimately control protein synthesis and cell metabolism. He also mapped the parallel Ras–ERK–RSK pathway.
The timeline below follows Blenis's mTOR-related discoveries in this Atlas.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 1992 | M | Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases CHU1992 Early evidence that the rapamycin–FKBP complex specifically blocks growth signalling through the p70 S6 kinases. |
| 1992 | M | Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase KUO1992 Rapamycin selectively inhibits IL-2-driven activation of p70 S6 kinase during T-cell proliferation. |
| 1999 | M | Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor BRU1999 Akt phosphorylates the Forkhead transcription factor FKHRL1 (a FOXO family member), driving its cytoplasmic retention via 14-3-3 binding and blocking Fas-ligand-driven apoptosis — the discovery that placed FOXO transcription factors downstream of Akt/PI3K survival signalling. |
| 2001 | A | An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice POD2001 Co-author: an mTOR inhibitor reduces tumour growth and normalises S6 kinase activity in Pten+/- mice. |
| 2002 | M | Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E FIN2002 Shows mammalian cell size is controlled by mTOR through its targets S6K1 and 4E-BP1/eIF4E. |
| 2002 | M | Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling TEE2002 Senior author: TSC1 and TSC2 together inhibit mTOR signalling to S6K1 and 4E-BP1, and block amino-acid reactivation of S6K1. |
| 2002 | M | Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway MAN2002 Co-author: Akt phosphorylates the TSC2 protein tuberin, and a tuberin mutant lacking these sites blocks S6K1 activation (cells). |
| 2003 | M | TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function SCH2003 The TOS motif mediates raptor binding and controls multisite 4E-BP1 phosphorylation by mTORC1. |
| 2003 | M | Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb TEE2003 TSC1-TSC2 acts as a GTPase-activating protein (GAP) for Rheb; when TSC is inactive, Rheb accumulates in its active GTP-bound form and activates mTOR signalling. |
| 2005 | M | mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events HOL2005 Reveals how mTOR and S6K1 assemble the translation machinery through ordered phosphorylation. |
| 2009 | R | Molecular mechanisms of mTOR-mediated translational control MAX2009 Review of the molecular mechanisms of mTOR-mediated translational control. |
| 2011 | M | Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling YUX2011 Phosphoproteomics identify Grb10 as an mTORC1 substrate driving negative feedback on insulin/PI3K. |
| 2015 | M | PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex LIU2015 PIP3 relieves SIN1 PH-domain autoinhibition to activate the mTORC2 kinase complex. |
| 2025 | R | mTORC1, the maestro of cell metabolism and growth HE2025 Comprehensive current review of how nutrients and growth signals are integrated by mTORC1 and the metabolic programs it commands, plus the clinical outlook for mTORC1-targeted therapy across cancer, neurodegeneration, obesity, diabetes and aging -- anchor reference for the pathway map. |
Co-authors in the Atlas 19
People with a profile here who share at least one study with John Blenis.
ShowHide
- Lewis C. Cantley 5 shared studies Co-discovered PI3K, the pathway that feeds into mTOR from growth factors
- Andrew R. Tee 3 shared studies First author of one of several 2003 papers showing that the TSC1–TSC2 complex acts as a GTPase-activating protein for Rheb
- Brendan D. Manning 3 shared studies Was among the groups that in 2002 identified TSC2 as a direct target of Akt (MAN2002), linking insulin and PI3K signalling to mTORC1, and later found TBC1D7 as the third subunit of the TSC complex. His lab has shown how mTORC1 turns growth signals into the synthesis of lipids and nucleotides
- Diane C. Fingar 3 shared studies Studies how mTORC1 and mTORC2 are regulated, especially through site-specific phosphorylation
- Gerald R. Crabtree 2 shared studies Helped define the calcineurin-NFAT pathway behind cyclosporine and FK506, and showed in 1992 that rapamycin blocks IL-2 activation of p70 S6 kinase.
- Steven P. Gygi 2 shared studies Mass-spectrometry scientist whose Harvard lab builds large-scale proteomics methods, including the BioPlex human protein-interaction map, and contributed proteomics to the discoveries of the CASTOR and SAMTOR nutrient sensors
- Anne Brunet Showed that Akt directly phosphorylates and controls FOXO, the transcription-factor switch linking insulin/IGF-1 signaling to lifespan
- Bing Su Immunologist who studies how mTOR and MAPK signaling shape immune regulation and vascular function, and senior author of the study showing that SIN1 is a core part of mTORC2.
- David J. Kwiatkowski Geneticist and physician who studies tuberous sclerosis complex (TSC) and the TSC1/TSC2 genes that restrain mTORC1.
- David M. Sabatini Identified mTOR (as RAFT1) in 1994. His lab then mapped much of the machinery around it: raptor and rictor at the core of mTORC1 and mTORC2, the Rag–Ragulator system that docks mTORC1 on the lysosome, and the sensors that detect leucine, arginine and SAM
- Charles L. Sawyers Physician-scientist known for targeted cancer drugs (ABL inhibitors in leukaemia, antiandrogens in prostate cancer); his UCLA lab helped show that PTEN-deficient tumour cells depend more on mTOR
- Katrina Podsypanina First author of the study showing that an mTOR inhibitor reduced tumour growth and S6 kinase activity in Pten+/- mice; later moved from cancer genetics to tumour immunology
- Long He Research faculty member in John Blenis's lab at Weill Cornell who studies how mTORC1 controls cell metabolism, and first author of the lab's 2025 review of mTORC1 as a conductor of metabolism and growth
- Marina K. Holz Cell biologist who, as a postdoc with John Blenis, showed how mTOR and S6K1 trade places on eIF3 to start protein synthesis, and who now studies mTOR in breast cancer and the rare lung disease LAM at New York Medical College
- Ramon Parsons Cancer geneticist whose Columbia group identified the PTEN tumour suppressor gene in 1997, in parallel with another team; his lab then studied what goes wrong downstream of PTEN loss, including mTOR
- Stefanie S. Schalm Cell biologist who, in John Blenis's lab, showed that the TOS motif lets raptor grab 4E-BP1 so mTORC1 can phosphorylate it, and who later moved into cancer drug discovery in the biotech industry
- Wenyi Wei Studies how protein stability and cell signalling, including the PI3K-mTOR-AKT network, are controlled in cancer cells.
- Xiaoju Max Ma Cell biologist who trained with John Blenis on how mTOR and S6K1 control protein synthesis, wrote a widely used review of mTOR-driven translation, and later worked in cancer research at Genentech
- Yonghao Yu Used phosphoproteomics to show that mTORC1 phosphorylates and stabilises Grb10, which then acts as a feedback brake on insulin and IGF-1 signalling
Every researcher with a profile →
Spotted something wrong or out of date about John Blenis?
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Was this page useful?
Thank you. Your answer was counted anonymously.